Pub Date : 2024-04-01DOI: 10.1016/j.acuroe.2023.10.004
C. Bostancı, D.Ö. Demir
Objective
To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.
Methods
191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of <0.15 ng/mL/mL, f/t PSA ratio of >0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD > 0.15 ng/mL/mL and f/t PSA ratio <15.
Results
NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD < 0.15 ng/mL/mL and f/t PSA > 15.
Conclusion
f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is >0.15 ng/mL/mL and the f/t PSA ratio is <0.15. However, we need randomized controlled studies with more patients to confirm our study.
{"title":"The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients","authors":"C. Bostancı, D.Ö. Demir","doi":"10.1016/j.acuroe.2023.10.004","DOIUrl":"10.1016/j.acuroe.2023.10.004","url":null,"abstract":"<div><h3>Objective</h3><p>To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.</p></div><div><h3>Methods</h3><p>191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of <0.15 ng/mL/mL, f/t PSA ratio of >0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD > 0.15 ng/mL/mL and f/t PSA ratio <15.</p></div><div><h3>Results</h3><p>NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD < 0.15 ng/mL/mL and f/t PSA > 15.</p></div><div><h3>Conclusion</h3><p>f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is >0.15 ng/mL/mL and the f/t PSA ratio is <0.15. However, we need randomized controlled studies with more patients to confirm our study.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 238-245"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.acuroe.2023.08.002
R. Correa , N. Vidal , A. Quesada-García , R. Marcos , J. Muñoz del Toro , J. Muñoz-Rodríguez
Introduction
The management of patients with prostate cancer (PCa) is established in clinical practice guidelines, which are based on randomized studies according to the level of evidence. In Spain, the degree of compliance with these guidelines in clinical practice is unknown.
Objectives
To describe the profiles of PCa patients at the time of diagnosis and the management of patients with localized PCa and those with BCR in Spain.
Materials & methods
A medical survey was conducted in specialized care (85 urologists [UROs], 64 radiation oncologists [ROs], and 21 medical oncologists [MOs]). Three questionnaires were developed for this study with 22 (UROs and ROs) or 21 questions (MOs).
Results
The annual incidence of PCa was 24,057 in participating hospitals (N = 131). The extrapolated annual incidence in Spain is 40,531 cases. The estimated prevalence of PCa in Spain is 221,689. Of note, 79% and 80% of patients seen by UROs and ROs, respectively had localized PCa at diagnosis. Biopsy was the most used diagnostic test among the three specialties, followed by abdominopelvic computer tomography. More than 90% of patients with BCR underwent standard tests. Next generation imaging tests and PET-choline/PSMA are still used residually. Most patients with localized PCa are currently treated with either surgery or radiotherapy, while for BCR patients, UROs and ROs prefer radiotherapy and MOs androgen deprivation therapy alone or in combination.
Conclusion
This study describes patient profiles at the time of diagnosis and provides an overview of the current therapeutic management of localized PCa and BCR in clinical practice in Spain.
{"title":"Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey","authors":"R. Correa , N. Vidal , A. Quesada-García , R. Marcos , J. Muñoz del Toro , J. Muñoz-Rodríguez","doi":"10.1016/j.acuroe.2023.08.002","DOIUrl":"10.1016/j.acuroe.2023.08.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The management of patients with prostate cancer (PCa) is established in clinical practice guidelines, which are based on randomized studies according to the level of evidence. In Spain, the degree of compliance with these guidelines in clinical practice is unknown.</p></div><div><h3>Objectives</h3><p>To describe the profiles of PCa patients at the time of diagnosis and the management of patients with localized PCa and those with BCR in Spain.</p></div><div><h3>Materials & methods</h3><p>A medical survey was conducted in specialized care (85 urologists [UROs], 64 radiation oncologists [ROs], and 21 medical oncologists [MOs]). Three questionnaires were developed for this study with 22 (UROs and ROs) or 21 questions (MOs).</p></div><div><h3>Results</h3><p>The annual incidence of PCa was 24,057 in participating hospitals (<em>N</em> = 131). The extrapolated annual incidence in Spain is 40,531 cases. The estimated prevalence of PCa in Spain is 221,689. Of note, 79% and 80% of patients seen by UROs and ROs, respectively had localized PCa at diagnosis. Biopsy was the most used diagnostic test among the three specialties, followed by abdominopelvic computer tomography. More than 90% of patients with BCR underwent standard tests. Next generation imaging tests and PET-choline/PSMA are still used residually. Most patients with localized PCa are currently treated with either surgery or radiotherapy, while for BCR patients, UROs and ROs prefer radiotherapy and MOs androgen deprivation therapy alone or in combination.</p></div><div><h3>Conclusion</h3><p>This study describes patient profiles at the time of diagnosis and provides an overview of the current therapeutic management of localized PCa and BCR in clinical practice in Spain.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 218-227"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173578623001002/pdfft?md5=98e0c64d8ebb8a4637c34d8285caad92&pid=1-s2.0-S2173578623001002-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10380038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.acuroe.2023.12.002
N. Gençtürk , A. Yıldız Karaahmet , S. Shafaati Laleh , Z. Guksu
Objectives
This systematic review and meta-analysis study aimed to examine the relationship between infertility and sleep quality in women.
Methods
The literature search was conducted between October and November 2022 with full-text studies from PubMed (MEDLINE), Cochrane, Google Scholar, and Scientific Information Database (SID). The study is based on the recommendations of the Cochrane guidelines. The data were analyzed using the Review Manager computer software (Version 5.3).
Results
A systematic literature review was conducted, with 11 studies included. The meta-analysis revealed a significant difference between infertility and sleep quality in women, that the sleep quality of infertile patients decreased (SMD: −0.75 95% CI: −0.84 to −0.66, Z = 16.46, P < .00001), and that there was a significant difference between infertility and depression (SMD: −0.18 95% CI: −0.27 to −0.09, Z = 4.00, P < .0001).
Conclusion
The results of this study indicate that sleep quality is low in infertile women.
{"title":"The relationship between infertility and sleep quality in women: Systematic review and meta-analysis","authors":"N. Gençtürk , A. Yıldız Karaahmet , S. Shafaati Laleh , Z. Guksu","doi":"10.1016/j.acuroe.2023.12.002","DOIUrl":"10.1016/j.acuroe.2023.12.002","url":null,"abstract":"<div><h3>Objectives</h3><p>This systematic review and meta-analysis study aimed to examine the relationship between infertility and sleep quality in women.</p></div><div><h3>Methods</h3><p>The literature search was conducted between October and November 2022 with full-text studies from PubMed (MEDLINE), Cochrane, Google Scholar, and Scientific Information Database (SID). The study is based on the recommendations of the Cochrane guidelines. The data were analyzed using the Review Manager computer software (Version 5.3).</p></div><div><h3>Results</h3><p>A systematic literature review was conducted, with 11 studies included. The meta-analysis revealed a significant difference between infertility and sleep quality in women, that the sleep quality of infertile patients decreased (SMD: −0.75 95% CI: −0.84 to −0.66, Z = 16.46, <em>P</em> < .00001), and that there was a significant difference between infertility and depression (SMD: −0.18 95% CI: −0.27 to −0.09, Z = 4.00, <em>P</em> < .0001).</p></div><div><h3>Conclusion</h3><p>The results of this study indicate that sleep quality is low in infertile women.</p><p>PROSPERO ID: (CRD42023404389).</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 185-203"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139072516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.acuroe.2023.10.002
P.M. Orbe Villota , J.A. Leiva Centeno , J. Lugones , P.G. Minuzzi , S.M. Varea
Objective
To compare the performance of the risk calculators of the European Randomized Study for Screening of Prostate Cancer (ERSPC) and the Prostate Biopsy Collaborative Group (PBCG) in predicting the risk of presenting clinically significant prostate cancer.
Material and methods
Retrospectively, patients who underwent prostate biopsy at Sanatorio Allende Cerro, Ciudad de Córdoba, Argentina, were identified from January 2018 to December 2021. The probability of having prostate cancer was calculated with the two calculators separately and then the results were compared to establish which of the two performed better. For this, areas under the curve (AUC) were analyzed.
Results
250 patients were included, 140 (56%) presented prostate cancer, of which 92 (65.71%) had clinically significant prostate cancer (Gleason score ≥7). The patients who presented cancer were older, had a higher prostate-specific antigen (PSA) value, and had a smaller prostate size. The AUC to predict the probability of having clinically significant prostate cancer was 0.79 and 0.73 for PBCG-RC and ERSPC-RC respectively (P = 0.0084).
Conclusion
In this cohort of patients, both prostate cancer risk calculators performed well in predicting clinically significant prostate cancer risk, although the PBCG-RC showed better accuracy.
{"title":"Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina","authors":"P.M. Orbe Villota , J.A. Leiva Centeno , J. Lugones , P.G. Minuzzi , S.M. Varea","doi":"10.1016/j.acuroe.2023.10.002","DOIUrl":"10.1016/j.acuroe.2023.10.002","url":null,"abstract":"<div><h3>Objective</h3><p><span>To compare the performance of the risk calculators of the European Randomized Study for Screening of Prostate Cancer (ERSPC) and the </span>Prostate Biopsy<span> Collaborative Group (PBCG) in predicting the risk of presenting clinically significant prostate cancer.</span></p></div><div><h3>Material and methods</h3><p>Retrospectively, patients who underwent prostate biopsy at Sanatorio Allende Cerro, Ciudad de Córdoba, Argentina, were identified from January 2018 to December 2021. The probability of having prostate cancer was calculated with the two calculators separately and then the results were compared to establish which of the two performed better. For this, areas under the curve (AUC) were analyzed.</p></div><div><h3>Results</h3><p>250 patients were included, 140 (56%) presented prostate cancer, of which 92 (65.71%) had clinically significant prostate cancer (Gleason score ≥7). The patients who presented cancer were older, had a higher prostate-specific antigen (PSA) value, and had a smaller prostate size. The AUC to predict the probability of having clinically significant prostate cancer was 0.79 and 0.73 for PBCG-RC and ERSPC-RC respectively (<em>P</em> <!-->=<!--> <!-->0.0084).</p></div><div><h3>Conclusion</h3><p>In this cohort of patients, both prostate cancer risk calculators performed well in predicting clinically significant prostate cancer risk, although the PBCG-RC showed better accuracy.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 210-217"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.acuroe.2023.10.001
M. Behvarz , S.A. Rahmani , E. Siasi Torbati , S. Danaei Mehrabad , M. Bikhof Torbati
Introduction
Infertility is one of the important phenomena in human reproduction. Genetic factors are the most important cause of male infertility. Here, we aimed to investigate the correlation between idiopathic male infertility and SNPs of the LHCGR (rs2293275) and NR5A1 (rs1057517779) genes in the Iranian-Azeri population.
Methods
This case-control study consisted of 100 males with infertility and 100 healthy males from the Iranian Azeri population. Genomic DNA isolation from whole blood samples and Tetra-primer amplification refractory mutation system-polymerase chain reaction (Tetra-ARMS-PCR) method was used for genotyping. The data analysis was performed by chi-square (χ2) and Fisher’s exact tests.
Results
Genotyping analysis for LHCGR (rs2293275) polymorphism indicated that the frequency of C in the case group was significantly higher than in the control group (P < .05). Moreover, genotyping analysis for NR5A1 (rs1057517779) polymorphism indicated that the frequencies of the A allele and heterozygote GA genotype in the case group were significantly higher than those in the control group (P < .05).
Conclusion
Our study demonstrated that the SNPs of LHCGR (rs2293275) and NR5A1 (rs1057517779) genes may play a critical role in male infertility in the Iranian Azeri population. However, further studies on other ethnic origins with larger sample sizes are essential for accessing more accurate results. Moreover, functional experiments might be needed to understand the role of these polymorphisms in the molecular pathways involved in male fertility.
{"title":"Correlation between LHCGR and NR5A1 genes polymorphism and male infertility risk","authors":"M. Behvarz , S.A. Rahmani , E. Siasi Torbati , S. Danaei Mehrabad , M. Bikhof Torbati","doi":"10.1016/j.acuroe.2023.10.001","DOIUrl":"10.1016/j.acuroe.2023.10.001","url":null,"abstract":"<div><h3>Introduction</h3><p><span>Infertility is one of the important phenomena in human reproduction. Genetic factors<span><span> are the most important cause of male infertility. Here, we aimed to investigate the correlation between idiopathic male infertility and </span>SNPs of the </span></span><span><span>LHCGR</span></span> (rs2293275) and <em>NR5A1</em> (rs1057517779) genes in the Iranian-Azeri population.</p></div><div><h3>Methods</h3><p>This case-control study consisted of 100 males with infertility and 100 healthy males from the Iranian Azeri population. Genomic DNA isolation from whole blood samples and Tetra-primer amplification refractory mutation system-polymerase chain reaction (Tetra-ARMS-PCR) method was used for genotyping. The data analysis was performed by chi-square (χ2) and Fisher’s exact tests.</p></div><div><h3>Results</h3><p>Genotyping analysis for <em>LHCGR</em> (rs2293275) polymorphism indicated that the frequency of C in the case group was significantly higher than in the control group (<em>P</em> < .05). Moreover, genotyping analysis for <em>NR5A1</em><span> (rs1057517779) polymorphism indicated that the frequencies of the A allele and heterozygote GA genotype in the case group were significantly higher than those in the control group (</span><em>P</em> < .05).</p></div><div><h3>Conclusion</h3><p>Our study demonstrated that the SNPs of <em>LHCGR</em> (rs2293275) and <em>NR5A1</em><span> (rs1057517779) genes may play a critical role in male infertility in the Iranian Azeri population. However, further studies on other ethnic origins with larger sample sizes are essential for accessing more accurate results. Moreover, functional experiments might be needed to understand the role of these polymorphisms in the molecular pathways involved in male fertility.</span></p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 246-253"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.acuroe.2023.10.006
A. Abu-Suboh Abadia , A. Abu-Suboh Abadia , L. Mosquera Seoane , P. Gómez Martínez , M.A. Trillo Lista , P. Portela Pereira , M.J. Martínez Barcina , J. Palou Redorta , O. Rodríguez Faba
Introduction
Due to their increasing prevalence and complex management, renal tumors are challenging for health professionals. The study aims to evaluate the usefulness of R.E.N.A.L. and PADUA nephrometry scores in the prediction of complications after percutaneous cryoablation.
Material and methods
The study prospectively analyzed 90 patients with 101 stage T1a renal cell carcinoma (RCC) tumors treated with cryoablation.
Results
Ninety patients with 101 small renal tumors who received cryoablative therapy were investigated. The mean age of the patients was 68 years and 74.4% were male. Most tumors were smaller than 4 cm (89.1%) and the mean PADUA and R.E.N.A.L. scores were 8.65 and 7.35, respectively. Complications were observed in 12 cases. PADUA and R.E.N.A.L. scores demonstrated moderate predictive power (AUC = 0.58 and AUC = 0.63, respectively) for post-cryoablation complications.
Conclusions
Percutaneous cryoablation is a safe and effective treatment for small renal tumors. The R.E.N.A.L. and PADUA renal nephrometry scores have moderate predictive power for complications associated with percutaneous cryoablation of renal tumors.
{"title":"Usefulness of renal nephrometry scoring systems in the prediction of complications associated to percutaneous image-guided treatment for small renal masses","authors":"A. Abu-Suboh Abadia , A. Abu-Suboh Abadia , L. Mosquera Seoane , P. Gómez Martínez , M.A. Trillo Lista , P. Portela Pereira , M.J. Martínez Barcina , J. Palou Redorta , O. Rodríguez Faba","doi":"10.1016/j.acuroe.2023.10.006","DOIUrl":"10.1016/j.acuroe.2023.10.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Due to their increasing prevalence and complex management, renal tumors are challenging for health professionals. The study aims to evaluate the usefulness of R.E.N.A.L. and PADUA nephrometry scores in the prediction of complications after percutaneous cryoablation.</p></div><div><h3>Material and methods</h3><p>The study prospectively analyzed 90 patients with 101 stage T1a renal cell carcinoma (RCC) tumors treated with cryoablation.</p></div><div><h3>Results</h3><p>Ninety patients with 101 small renal tumors who received cryoablative therapy were investigated. The mean age of the patients was 68 years and 74.4% were male. Most tumors were smaller than 4 cm (89.1%) and the mean PADUA and R.E.N.A.L. scores were 8.65 and 7.35, respectively. Complications were observed in 12 cases. PADUA and R.E.N.A.L. scores demonstrated moderate predictive power (AUC = 0.58 and AUC = 0.63, respectively) for post-cryoablation complications.</p></div><div><h3>Conclusions</h3><p>Percutaneous cryoablation is a safe and effective treatment for small renal tumors. The R.E.N.A.L. and PADUA renal nephrometry scores have moderate predictive power for complications associated with percutaneous cryoablation of renal tumors.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 2","pages":"Pages 155-161"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.acuroe.2023.11.002
R. Uğur, A. Şimşek
Introduction
The aim of this study is to evaluate and compare erection function (EF) after Excision and Primary Anastomosis Urethroplasty (EPAU) and Buccal Mucosal Graft Urethroplasty (BMGU) in bulbar urethral stricture.
Methods
Patients who underwent urethroplasty were identified retrospectively. The criteria for inclusion in the study were determined as being over 18 years old and under 70 years old, being sexually active. Exclusion criteria are; preoperative severe erectile dysfunction, stricture outside the bulbar urethra, psychosocial incompatibility, urethral stricture related to pelvic fracture, follow-up time less than a year. As the primary endpoint, the International Index of Erectile Function-5 (IIEF-5) was determined as a comparison of EF in the preoperative and third, sixth and twelfth months after surgery. The secondary endpoint was the evaluation of the effects of demographic data, stricture and treatment characteristics on EF.
Results
Fifty patients were identified considering the inclusion/exclusion criteria. It was observed that there were 30 patients who underwent EPAU and 20 patients who underwent BMGU. At the third month after surgery, EF showed a statistically significant decrease in the EPAU group. In both patient groups, it was observed that the early negative effects after the operation in EF started to improve in the sixth month and returned to the baseline level by the first year.
Conclusion
EPAU and BMGU techniques have a similar effect on EF in the medium and long term. Both methods can be used safely and effectively in the appropriate patient group.
{"title":"The best method for erection function in urethroplasty; is excision and primary anastomosis or buccal mucosal graft urethroplasty?","authors":"R. Uğur, A. Şimşek","doi":"10.1016/j.acuroe.2023.11.002","DOIUrl":"10.1016/j.acuroe.2023.11.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The aim of this study is to evaluate and compare erection function (EF) after Excision and Primary Anastomosis<span><span> Urethroplasty (EPAU) and Buccal Mucosal Graft Urethroplasty (BMGU) in bulbar </span>urethral stricture.</span></p></div><div><h3>Methods</h3><p>Patients who underwent urethroplasty were identified retrospectively. The criteria for inclusion in the study were determined as being over 18 years old and under 70 years old, being sexually active. Exclusion criteria are; preoperative severe erectile dysfunction<span>, stricture outside the bulbar urethra, psychosocial incompatibility, urethral stricture related to pelvic fracture<span>, follow-up time less than a year. As the primary endpoint, the International Index of Erectile Function-5 (IIEF-5) was determined as a comparison of EF in the preoperative and third, sixth and twelfth months after surgery. The secondary endpoint was the evaluation of the effects of demographic data, stricture and treatment characteristics on EF.</span></span></p></div><div><h3>Results</h3><p>Fifty patients were identified considering the inclusion/exclusion criteria. It was observed that there were 30 patients who underwent EPAU and 20 patients who underwent BMGU. At the third month after surgery, EF showed a statistically significant decrease in the EPAU group. In both patient groups, it was observed that the early negative effects after the operation in EF started to improve in the sixth month and returned to the baseline level by the first year.</p></div><div><h3>Conclusion</h3><p>EPAU and BMGU techniques have a similar effect on EF in the medium and long term. Both methods can be used safely and effectively in the appropriate patient group.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 2","pages":"Pages 170-176"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138049122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1016/j.acuroe.2023.08.004
C. Calzas Montalvo , J. Medina-Polo , N.R. Miranda Utrera , S. Juste Álvarez , A. de la Calle Moreno , M.P. Caro González , R. Santos Perez de la Blanca , M. Hernández Arroyo , E. Peña Vallejo , J. Teigell Tobar , J.M. Duarte Ojeda , M. Pamplona Casamayor , Á. Tejido Sánchez , L. García González , A. Arrébola Pajares , Á. Sánchez Guerrero , J. Rodríguez de la Calle , A. Rodríguez Antolín
Introduction and objectives
Transplant renal artery stenosis (TRAS) is a vascular complication after kidney transplantation which estimated incidence is 13%. It could cause refractory arterial hypertension, kidney dysfunction and premature death in transplant recipients.
Methods
We carried out a retrospective study including every patient who underwent renal transplantation between 2014 and 2020. They were evaluated with a systematic post-transplant renal Doppler ultrasound. To identify independent risk factors for transplant renal artery stenosis we performed a multivariate analysis.
Results
Seven hundred twenty-four kidney transplants were included, 12% were living donors and 88% were deceased donors. The mean age was 54.8 in recipients and 53 in donors. Transplant renal artery stenosis was diagnosed in 70 (10%) recipients, the majority in the first 6 months after surgery. 51% of patients with transplant renal artery stenosis were managed conservatively. The multivariate analysis showed diabetes mellitus, graft rejection, arterial resuture and donor body mass index as independent risk factors for transplant renal artery stenosis. Survival of the grafts with transplant renal artery stenosis was 98% at 6 months and 95% at two years.
Conclusions
The systematic performance of Doppler ultrasound in the immediate post-transplant period diagnosed 10% of transplant renal artery stenosis in our cohort. Despite the above risk factors, an adequate monitoring and treatment could avoid the increased risk of graft loss in patients with transplant renal artery stenosis.
{"title":"Transplant renal artery stenosis: Study of incidence using doppler ultrasound, risk factors and analysis is effect in graft outcomes","authors":"C. Calzas Montalvo , J. Medina-Polo , N.R. Miranda Utrera , S. Juste Álvarez , A. de la Calle Moreno , M.P. Caro González , R. Santos Perez de la Blanca , M. Hernández Arroyo , E. Peña Vallejo , J. Teigell Tobar , J.M. Duarte Ojeda , M. Pamplona Casamayor , Á. Tejido Sánchez , L. García González , A. Arrébola Pajares , Á. Sánchez Guerrero , J. Rodríguez de la Calle , A. Rodríguez Antolín","doi":"10.1016/j.acuroe.2023.08.004","DOIUrl":"10.1016/j.acuroe.2023.08.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p><span>Transplant renal artery stenosis<span> (TRAS) is a vascular complication after kidney transplantation which estimated incidence is 13%. It could cause refractory arterial hypertension, </span></span>kidney dysfunction and premature death in transplant recipients.</p></div><div><h3>Methods</h3><p><span>We carried out a retrospective study including every patient who underwent renal transplantation between 2014 and 2020. They were evaluated with a systematic post-transplant renal Doppler ultrasound<span>. To identify independent risk factors for transplant renal artery stenosis we performed a </span></span>multivariate analysis.</p></div><div><h3>Results</h3><p>Seven hundred twenty-four kidney transplants were included, 12% were living donors and 88% were deceased donors. The mean age was 54.8 in recipients and 53 in donors. Transplant renal artery stenosis was diagnosed in 70 (10%) recipients, the majority in the first 6 months after surgery. 51% of patients with transplant renal artery stenosis were managed conservatively. The multivariate analysis showed diabetes mellitus, graft rejection<span>, arterial resuture and donor body mass index as independent risk factors for transplant renal artery stenosis. Survival of the grafts with transplant renal artery stenosis was 98% at 6 months and 95% at two years.</span></p></div><div><h3>Conclusions</h3><p><span><span>The systematic performance of Doppler ultrasound in the immediate post-transplant period diagnosed 10% of transplant renal artery stenosis in our cohort. Despite the above risk factors, an adequate monitoring and treatment could avoid the increased risk of </span>graft loss </span>in patients with transplant renal artery stenosis.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 2","pages":"Pages 177-183"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10380040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}